Get the Stockscreener App
15.61
2.80%
-0.45
After Hours:
15.61
Kalvista Pharmaceuticals Inc stock is traded at $15.61, with a volume of 782.26K.
It is down -2.80% in the last 24 hours and down -3.22% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$16.06
Open:
$15.67
24h Volume:
782.26K
Relative Volume:
0.73
Market Cap:
$789.03M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-4.2304
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
-1.01%
1M Performance:
-3.22%
6M Performance:
+10.24%
1Y Performance:
+43.61%
1-Day Range:
$15.27
$15.88
1-Week Range:
$15.26
$16.47
52-Week Range:
$9.235
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.61 | 811.77M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.11 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.02 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Reiterated | Needham | Buy |
| Jan-06-26 | Reiterated | Needham | Buy |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - BioSpace
KalVista presents sebetralstat data showing early treatment impact By Investing.com - Investing.com India
Market Trends: How does KalVista Pharmaceuticals Inc perform in inflationary periodsWatch List & Low Risk Growth Stock Ideas - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook with a Promising 115% Upside Potential - DirectorsTalk Interviews
Ekterly use urged for kids with HAE 12 and older in new international guideline - Angioedema News
How Kalvista Pharmaceuticals Inc. (KALV) Affects Rotational Strategy Timing - Stock Traders Daily
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Joplin Globe
KalVista Pharma chief development officer sells $67,668 in stock - Investing.com
KalVista Pharma CCO Sweeny Sold $61,878 in Stock - Investing.com UK
Kalvista Pharma CFO Piekos sells $27,506 in shares By Investing.com - Investing.com Australia
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 5,354 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock - MarketBeat
KalVista Pharma CMO Audhya sells $83k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations - Investing.com Australia
KalVista Pharma chief development officer sells $67,668 in stock By Investing.com - Investing.com Canada
Kalvista Pharma CFO Piekos sells $27,506 in shares - Investing.com
KalVista Pharma CMO Audhya sells $83k in shares - Investing.com India
[Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
KalVista (NASDAQ: KALV) CFO details RSU vesting and sell-to-cover sale - Stock Titan
KalVista Pharma CCO Sweeny Sold $61,878 in Stock By Investing.com - Investing.com UK
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet - Finviz
Skandinaviska Enskilda Banken AB publ Buys 160,128 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Bausch Health Companies (BHC) and Insulet (PODD) - The Globe and Mail
KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Investors Eye 113.97% Potential Upside - DirectorsTalk Interviews
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 1,038 Shares of Stock - MarketBeat
KalVista's Ekterly Recommended as First-Line Treatment for HAE i - GuruFocus
International guideline recommends EKTERLY as first-line HAE therapy - Investing.com Nigeria
International guideline recommends EKTERLY as first-line HAE therapy By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline - BioSpace
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for - PharmiWeb.com
KalVista's Ekterly Recommended as First-Line Treatment for HAE in Adolescents - GuruFocus
KalVista Pharmaceuticals (KALV) Leads in Short Interest Among Bi - GuruFocus
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ - openPR.com
KalVista (KALV) and Intellia (NTLA) Lead Short Interest Surge in Small-Cap Biotech - GuruFocus
KalVista Pharmaceuticals Q3 2026 Earnings Preview - MSN
(KALV) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. face regulatory challengesMarket Sentiment Review & Daily Stock Trend Reports - mfd.ru
Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock - MarketBeat
Will KalVista Pharmaceuticals Inc. stock benefit from automationJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
KalVista Pharmaceuticals (KALV) Stock Analysis: Unpacking A 123% Potential Upside - DirectorsTalk Interviews
Hereditary Angioedema Market to Surpass USD 3 Billion Baseline in 2023, Set for Robust Growth Through 2034 Across 7MM with 7,000 Diagnosed US Cases | DelveInsight - Barchart.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of All - pharmiweb.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - BioSpace
(sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Business Wire
Travel Stocks: Should I hold or sell KalVista Pharmaceuticals Inc nowM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha
Is KalVista Pharmaceuticals Inc. a turnaround storyMarket Risk Report & Momentum Based Trading Signals - mfd.ru
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Market Catalysts: Does Global Blue Group Holding AG Equity Warrant have a sustainable dividendTrend Reversal & Safe Capital Preservation Plans - baoquankhu1.vn
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):